New legislation aimed at severing the close ties between the US FDA and drug companies has been introduced in the US.

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1488, 2005-01, pp. : 21-21

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Astellas Pharma's Supplemental New Drug Application (sNDA) for injectable micafungin [Mycamine] has been approved by the US FDA.

By  

Inpharma, Vol. 1, Iss. 1623, 2008-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

A new action plan aimed at combating antimicrobial resistance in the US has been released

By  

Inpharma, Vol. 1, Iss. 1273, 2001-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

The US government's plans to end the pay-for-delay agreements between pharmaceutical and generic companies has been criticised

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 623, 2011-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

The endpoints used by the US FDA to approve new oncology drug applications have been summarised

By  

Inpharma, Vol. 1, Iss. 1387, 2003-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Amendments to the requirements for brandname-drug patents have been proposed by the US FDA

By  

Inpharma, Vol. 1, Iss. 1368, 2002-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite